Department of Hematology, The First Hospital of Jilin University, Changchun, Jilin, China.
Department of Hematopathology, Duke Cancer Institute, Duke University Medical Center, Durham, NC, United States.
Front Immunol. 2023 Jul 7;14:1216610. doi: 10.3389/fimmu.2023.1216610. eCollection 2023.
Advanced studies have shown a biological correlation between hepatitis B virus (HBV) and B-cell lymphoma, especially diffuse large B-cell lymphoma (DLBCL). Patients with DLBCL infected with HBV (HBV-associated DLBCL) are clinically characterized by an advanced clinical stage, poor response to front-line immunochemotherapy regimens, and worse clinical prognosis. HBV-associated DLBCL often exhibits abnormal activation of the nuclear factor kappa B pathway as well as mutations in oncogenes, including and . Currently, there is no consensus on any specific and effective treatment for HBV-associated DLBCL. Therefore, in this review, we comprehensively and mechanistically analyzed the natural history of HBV infection and immunity, including HBV-mediated oncogenes, immune escape, epigenetic alterations, dysregulated signaling pathways, and potential therapeutic approaches for HBV-associated DLBCL. We hope that an improved understanding of the biology of HBV-associated DLBCL would lead to the development of novel therapeutic approaches, enhance the number of effective clinical trials, and improve the prognosis of this disease.
研究表明，乙型肝炎病毒（HBV）与 B 细胞淋巴瘤，尤其是弥漫性大 B 细胞淋巴瘤（DLBCL）之间存在生物学相关性。感染 HBV 的 DLBCL 患者（HBV 相关的 DLBCL）具有临床分期较晚、对一线免疫化疗方案反应不佳和临床预后较差的特点。HBV 相关的 DLBCL 常表现为核因子 κB 通路的异常激活和癌基因的突变，包括 和 。目前，对于 HBV 相关的 DLBCL 尚无任何特定和有效的治疗方法。因此，在这篇综述中，我们全面而深入地分析了 HBV 感染和免疫的自然史，包括 HBV 介导的致癌基因、免疫逃逸、表观遗传改变、失调的信号通路以及 HBV 相关的 DLBCL 的潜在治疗方法。我们希望对 HBV 相关的 DLBCL 的生物学有更深入的了解，从而开发出新的治疗方法，增加有效的临床试验数量，并改善该疾病的预后。
